Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031330 | 0.85 | PTGS2 (0.73) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL6036720 | 0.78 | PTGS2 (0.46) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL5534966 | 0.74 | PTGS2 (0.79) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL17917294 | 0.74 | PTGS2 (0.85) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL13688515 | 0.73 | PTGS2 (0.70) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL27462222 | 0.73 | PTGS2 (0.41) | PTGS2HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17208147 | 0.72 | PTGS2 (0.79) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL13633978 | 0.71 | PTGS2 (0.80) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL16746714 | 0.71 | PTGS2 (0.65) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL6036175 | 0.70 | PTGS2 (0.78) | PTGS2PTGS1ABCB11PPARGNR1I3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115662-B2 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | NOVARTIS AG (CH) | 2006-10-03 | — | — | US | disclosed |
| US-20040122254-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2004-06-24 | — | — | US | disclosed |
| US-6727281-B2 | SELECTIVE CYCLOOXYGENASE-2(COX-2) INHIBITORS | NOVARTIS AG (CH) | 2004-04-27 | — | — | US | disclosed |
| EP-1007505-B1 | CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND DERIVATIVES | NOVARTIS AG (CH) | 2003-04-16 | — | — | EP | disclosed |
| US-20020183391-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2002-12-05 | — | — | US | disclosed |
| US-6451858-B2 | FOR THERAPY OF INFLAMMATION, PYRESIS, PAIN, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, MIGRAINE HEADACHE, CANCER, MELANOMA, MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE, OSTEOPOROSIS, ASTHMA, LUPUS AND PSORIASIS; SIDE EFFECT REDUCTION | NOVARTIS AG (CH) | 2002-09-17 | — | — | US | disclosed |
| US-20020013369-A1 | Certain 5-alkyl-2arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2002-01-31 | — | — | US | disclosed |
| US-6310099-B1 | 5-METHYL OR ETHYL-2-(2-'CHLORO OR FLUORO OR TRIFLUROMETHYL-6'FLUORO OR CHLOROANILINO) PHENYLACETIC ACID OR SALT IS USED AS COX-2 SELECTIVE CYCLOOXYGENASE INHIBITOR | NOVARTIS AG (CH) | 2001-10-30 | — | — | US | disclosed |
| US-6291523-B1 | SELECTIVE COX-2 CYCLOOXYGENASE INHIBITORS | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | disclosed |
| EP-1007505-A1 | CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND DERIVATIVES | Novartis AG (CH) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999011605-A1 | CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND DERIVATIVES | NOVARTIS AG (CH) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013369-A1 | Certain 5-alkyl-2arylaminophenylacetic acids and derivatives | HCAR2, CYP2F1, CYP2E1 | PTGS2 5/4885PTGS1 4/4885ABCB11 694/4885 |
| US-20040122254-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | CYP2F1, CYP2E1, PTGER1 | PTGS2 8/4885PTGS1 5/4885ABCB11 387/4885 |
| US-20020183391-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | CYP2F1, CYP2E1, PTGER1 | PTGS2 8/4885PTGS1 5/4885ABCB11 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.